Join Dr. Victoria Werth as she shares the unmet needs and management challenges experienced by patients with bullous pemphigoid (BP), including physical, mental, socioeconomic, and treatment-related burdens. She expands on the comorbidities and increased mortality rates these patients may face.
Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.

Welcome to the BP learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

Join Dr. Werth as she outlines how early diagnosis and treatment are critical to minimize risk and improve long term outcomes in patients with BP.
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP

Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.